Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.

Abstract:

BACKGROUND:Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research the features and risk factors of ILD in advanced non-small cell lung cancer (NSCLC). METHODS:Between December 2015 and November 2018, 130 advanced NSCLC patients were treated with nivolumab, pembrolizumab or atezolizumab. The patients were categorized into two groups (irAEs group or non-irAEs group). Subsequently, we divided the irAEs group into two groups based on the incidence of ILD (ILD group and irAEs-non-ILD group). Treatment efficacy and the characteristics of ILD were evaluated. RESULTS:A total of 39 (30%) patients developed irAEs. ILD was observed in 16 (12%) patients. Patients with ILD had a higher objective response rate (ORR) compared with irAEs-non-ILD patients and non-irAEs patients (63%, 43% and 22%, respectively). Median progression-free survival (mPFS) was 15.9 months in ILD patients, 5.4 months in irAEs-non-ILD patients and 3.3 months in non-irAEs patients (log-rank test, P = 0.033). Pre-existing interstitial pneumonia (IP) was an independent risk factor for ILD-induced ICIs (odds ratio [OR] 14.7; 95% confidence interval [CI]: 2.16-99.6, P = 0.006). CONCLUSIONS:ORR and PFS were significantly better in ILD patients than in irAEs-non-ILD and non-irAEs patients. Pre-existing history of IP was an independent risk factor for ILD-induced ICIs.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Sugano T,Seike M,Saito Y,Kashiwada T,Terasaki Y,Takano N,Hisakane K,Takahashi S,Tanaka T,Takeuchi S,Miyanaga A,Minegishi Y,Noro R,Kubota K,Gemma A

doi

10.1111/1759-7714.13364

subject

Has Abstract

pub_date

2020-04-01 00:00:00

pages

1052-1060

issue

4

eissn

1759-7706

issn

1759-7714

journal_volume

11

pub_type

杂志文章
  • Prevalence, risk factors and survival of lung cancer in the idiopathic pulmonary fibrosis.

    abstract:BACKGROUND:The aim of this study was to evaluate the prevalence, risk factors, and survival of lung cancer in patients with idiopathic pulmonary fibrosis (IPF). METHODS:IPF with lung cancer from tertiary hospitals consisted of 1685 patients who had been diagnosed between 2003 and 2007. We reviewed their medical record...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2011.00107.x

    authors: Lee KJ,Chung MP,Kim YW,Lee JH,Kim KS,Ryu JS,Lee HL,Park SW,Park CS,Uh ST,Lee YC,Park SJ,Kim KH,Jeon YJ,Choi WI,Park YB,Kim DS,Jeong SH,Lee JH,Park MS

    更新日期:2012-05-01 00:00:00

  • Hsa_circRNA_0000518 facilitates breast cancer development via regulation of the miR-326/FGFR1 axis.

    abstract:BACKGROUND:Breast cancer (BC) is a heterogeneous malignant tumor that threatens the health of women worldwide. Hsa_circRNA_0000518 (circ_0000518) has been revealed to be upregulated in BC tissues. However, the role and mechanism of circ_0000518 in BC are indistinct. METHODS:Quantitative real-time polymerase chain reac...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13641

    authors: Jiang J,Lin H,Shi S,Hong Y,Bai X,Cao X

    更新日期:2020-11-01 00:00:00

  • Nm23-H1 inhibits lung cancer bone-specific metastasis by upregulating miR-660-5p targeted SMARCA5.

    abstract:BACKGROUND:Nm23-H1 gene has been found to be an inhibitor of tumor metastasis in lung cancer. MicroRNAs (miRNAs) play key roles in tumor metastasis through multiple signaling pathways. This study explored whether the nm23-H1 gene could inhibit invasion and metastasis of lung cancer cells by regulating miRNA-660-5p targ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13308

    authors: Ai C,Ma G,Deng Y,Zheng Q,Gen Y,Li W,Li Y,Zu L,Zhou Q

    更新日期:2020-03-01 00:00:00

  • A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer.

    abstract:BACKGROUND:To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). METHODS:Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two gro...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13238

    authors: Nie K,Zhang Z,You Y,Zhuang X,Zhang C,Ji Y

    更新日期:2020-01-01 00:00:00

  • Experience with the "da Vinci" robotic system for early-stage thymomas: Report of 23 cases.

    abstract:BACKGROUND:The aim of this study was to report a single referral center experience in robotic extended thymectomy for clinical early stage thymomas, evaluating its safety, feasibility and efficacy, with special regard to oncological outcomes. METHODS:Between January 2009 and December 2012, we retrospectively selected ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12097

    authors: Huang P,Ye B,Yang Y,Tantai JC,Zhao H

    更新日期:2014-07-01 00:00:00

  • Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.

    abstract:BACKGROUND:ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better progno...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12791

    authors: Kang J,Chen HJ,Zhang XC,Su J,Zhou Q,Tu HY,Wang Z,Wang BC,Zhong WZ,Yang XN,Chen ZH,Ding Y,Wu X,Wang M,Fu JG,Yang Z,Zhang X,Shao YW,Wu YL,Yang JJ

    更新日期:2018-09-01 00:00:00

  • Human leukocyte antigen (HLA)-G gene polymorphism in patients with non-small cell lung cancer.

    abstract:BACKGROUND:Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human le...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12232

    authors: Kowal A,Wiśniewski A,Kuśnierczyk P,Jankowska R

    更新日期:2015-09-01 00:00:00

  • Outcome of active anti-cancer treatment in elderly patients with advanced non-small cell lung cancer: A single center experience.

    abstract:BACKGROUND:This study aimed to evaluate the characteristics of active anti-cancer treatment (AAT) compared with best supportive care (BSC) in elderly patients with advanced non-small cell lung cancer (NSCLC). METHODS:A retrospective analysis of 144 patients, aged 70 or older, with stage IIIb/IV NSCLC from 672 patients...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12066

    authors: Kim JH,Ryu MS,Ryu YJ,Lee JH,Shim SS,Kim Y,Chang JH

    更新日期:2014-03-01 00:00:00

  • A nurse-driven enhanced recovery after surgery (ERAS) nursing program for geriatric patients following lung surgery.

    abstract::Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13372

    authors: Li Y,Yan C,Li J,Wang Q,Zhang J,Qiang W,Qi D

    更新日期:2020-04-01 00:00:00

  • Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review.

    abstract::Here, we report two cases of advanced non-small cell lung cancer (NSCLC) in patients with negative driver genes who received ICI treatment for less than two years but continued to benefit from their administration after drug withdrawal. The first patient was diagnosed with left lung adenocarcinoma, cT1cN3M1c, stage IV...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13600

    authors: Shan Q,Wang H,Han X,Guo J,Wang Z

    更新日期:2020-10-01 00:00:00

  • Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.

    abstract:BACKGROUND:Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non-invasively predict the TMB status and driver mutations in patients with resectable earl...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13163

    authors: Wang X,Kong C,Xu W,Yang S,Shi D,Zhang J,Du M,Wang S,Bai Y,Zhang T,Chen Z,Ma Z,Wang J,Dong G,Sun M,Yin R,Chen F

    更新日期:2019-10-01 00:00:00

  • Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion.

    abstract:BACKGROUND:Patients with malignant pleural effusion have a limited life expectancy. An increase in pleural and oncological treatment options and more accurate prognostic evaluation may help individualize treatment strategies. The aim of this study was to identify the prognostic indicators of overall survival (OS) after...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12354

    authors: Yoon DW,Cho JH,Choi YS,Kim J,Kim HK,Zo JI,Shim YM

    更新日期:2016-07-01 00:00:00

  • Attempt of peripheral nerve reconstruction during lung cancer surgery.

    abstract:BACKGROUND:Vagus nerve and recurrent laryngeal nerve (RLN) injury are not rare complications of lung cancer surgery and can cause lethal consequences. Until now, no optimal method other than paying greater attention during surgery has been available. METHODS:Four patients underwent lung surgery that involved RLN or va...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12619

    authors: Li H,Hu Y,Huang J,Yang Y,Xing K,Luo Q

    更新日期:2018-05-01 00:00:00

  • Management of immune checkpoint inhibitor-related dermatologic adverse events.

    abstract::Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The unique spectrum of immune-related adverse events (IrAEs) may occur during treatment. Dermatologic toxicities appear to be one of the most prevalent immunotherapy-related adverse events. The most common symptoms are maculopapular rash and pru...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13275

    authors: Si X,He C,Zhang L,Liu X,Li Y,Wang H,Guo X,Zhou J,Duan L,Wang M,Zhang L

    更新日期:2020-02-01 00:00:00

  • Clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: A multicenter study of the Anatolian Society of Medical Oncology (ASMO).

    abstract:BACKGROUND:Soft tissue sarcomas (STSs) are rare malignant tumors of embryogenic mesoderm origin. Primary thoracic STSs account for a small percentage of all STSs and limited published information is available. This study aimed to identify the prognostic factors for thoracic STSs and evaluate the disease's clinical outc...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12150

    authors: Unal OU,Oztop I,Yasar N,Urakci Z,Ozatli T,Bozkurt O,Sevinc A,Gunaydin Y,Yapar Taskoylu B,Arpaci E,Ulas A,Kodaz H,Tonyali O,Avci N,Aksoy A,Yilmaz AU

    更新日期:2015-01-01 00:00:00

  • Serum exosomal miR-1269a serves as a diagnostic marker and plays an oncogenic role in non-small cell lung cancer.

    abstract:BACKGROUND:Early diagnosis improves the prognosis for non-small cell lung cancer (NSCLC); therefore, there is a pressing need for effective diagnostic methods for NSCLC. Increasing evidence indicates that serum exosomal micro RNAs (miRNAs) represent promising diagnostic and prognostic markers for multiple cancers. Here...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13644

    authors: Wang X,Jiang X,Li J,Wang J,Binang H,Shi S,Duan W,Zhao Y,Zhang Y

    更新日期:2020-12-01 00:00:00

  • Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes.

    abstract:BACKGROUND:Both hypoxia and oncogenic mutations rewire tumor metabolism. In this study, glucose and glutamine metabolism-related markers were examined in stage I - resectable stage IIIA non-small cell lung cancer (NSCLC). Furthermore, expression of metabolism-related markers was correlated with mutational status to exa...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13226

    authors: Meijer TWH,Looijen-Salamon MG,Lok J,van den Heuvel M,Tops B,Kaanders JHAM,Span PN,Bussink J

    更新日期:2019-12-01 00:00:00

  • Osimertinib-induced severe interstitial lung disease: A case report.

    abstract::Lung cancer is globally one of the leading causes of malignant tumor-related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78-year-old ma...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13127

    authors: Fan M,Mo T,Shen L,Yang L

    更新日期:2019-07-01 00:00:00

  • Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR.

    abstract:BACKGROUND:The standard of care for fit locally advanced non-small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA-mEGFR), the role of EGFR-tyrosine kinase inhibitors (TKIs) is not clear. We compared CCRT versus TKI...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12847

    authors: Hsia TC,Liang JA,Li CC,Chien CR

    更新日期:2018-11-01 00:00:00

  • Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients.

    abstract:BACKGROUND:Achaete-scute homolog 1 (ASCL1) is a basic helix-loop-helix transcription factor and is essential in the differentiation of neuroendocrine cells and neural tissues. ASCL1 is frequently overexpressed in small cell lung cancer (SCLC) and plays a crucial role in the pathogenesis of SCLC. METHODS:This study was...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13212

    authors: Kim JH,Lee SY,Choi JE,Do SK,Lee JH,Hong MJ,Kang HG,Lee WK,Shin KM,Jeong JY,Choi SH,Lee YH,Seo H,Yoo SS,Lee J,Cha SI,Kim CH,Park JY

    更新日期:2020-01-01 00:00:00

  • Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients.

    abstract:BACKGROUND:Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13143

    authors: Haratake N,Seto T,Takamori S,Toyozawa R,Nosaki K,Miura N,Ohba T,Toyokawa G,Taguchi K,Yamaguchi M,Shimokawa M,Takenoyama M

    更新日期:2019-09-01 00:00:00

  • Clinical effect of bronchial arterial infusion chemotherapy and CalliSpheres drug-eluting beads in patients with stage II-IV lung cancer: A prospective cohort study.

    abstract:BACKGROUND:CalliSpheres are drug-eluting beads used for tumor artery embolization, with clinical benefits in a number of cancer types. The aim of the study was to examine the clinical benefits and complications of patients with stage II-IV lung cancer treated with CalliSpheres drug-eluting beads for embolization versus...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13522

    authors: Shang B,Li J,Wang X,Li D,Liang B,Wang Y,Han X,Dou W,Chen G,Shang J,Jiang S

    更新日期:2020-08-01 00:00:00

  • MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.

    abstract:BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13326

    authors: Zuo J,Zhao M,Fan Z,Liu B,Wang Y,Li Y,Lv P,Xing L,Zhang X,Shen H

    更新日期:2020-03-01 00:00:00

  • Surgical results of resectable small cell lung cancer.

    abstract:BACKGROUND:The standard of care for patients with small cell lung cancer (SCLC) is chemotherapy and radiotherapy, even for patients with limited disease. To define the role of surgical resection in patients with limited SCLC, we investigated the outcomes of patients diagnosed with limited-stage disease (LD) SCLC. METH...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12154

    authors: Kawano D,Okamoto T,Fujishita T,Suzuki Y,Kitahara H,Shimamatsu S,Maehara Y

    更新日期:2015-03-01 00:00:00

  • Nevirapine inhibits migration and invasion in dedifferentiated thyroid cancer cells.

    abstract:BACKGROUND:Metastatic or recurrent thyroid cancer often behaves aggressively, and approximately two-thirds of patients present with radioiodine resistance. Effective therapies to suppress thyroid cancer metastasis are urgently needed. Nevirapine has been proved to suppress tumor growth and induce differentiation in sev...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13211

    authors: Shang H,Zhao J,Yao J,Wang H,Wang S,Dong J,Liao L

    更新日期:2019-12-01 00:00:00

  • Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.

    abstract:BACKGROUND:Lung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13526

    authors: Kasahara N,Imai H,Naruse I,Tsukagoshi Y,Kotake M,Sunaga N,Kaira K,Maeno T,Asao T,Hisada T

    更新日期:2020-08-01 00:00:00

  • Pleomorphic adenoma presenting with a mediastinal mass.

    abstract::Pleomorphic adenoma is the most common type of salivary gland tumor. Although it rarely affects the trachea and bronchus, it usually grows in the airway and presents as an endobronchial mass. We recently experienced a case of pleomorphic adenoma originating in the bronchus and growing outward into the mediastinum. We ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12013

    authors: Lee YK,Kim YH,Kim GY,Youn HC

    更新日期:2014-01-01 00:00:00

  • Comparative study of esophagectomy, endoscopic therapy, and radiotherapy for cT1N0M0 esophageal cancer in elderly patients: A SEER database analysis.

    abstract:BACKGROUND:The number of patients diagnosed with early stage disease (T1a or T1b) has been increasing. This study was conducted to investigate the effect of esophagectomy (ES), endoscopic therapy (ET), and radiotherapy (RT) on long-term survival in elderly patients with cT1N0M0 esophageal cancer. METHODS:We searched t...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13080

    authors: Qin J,Peng Y,Chen W,Ma H,Zheng Y,Li Y,Wang J

    更新日期:2019-07-01 00:00:00

  • Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.

    abstract:BACKGROUND:Currently, there are no standard regimens for metastatic breast cancer patients (MBC) who have failed ≥ 3 chemotherapy treatments. The aim of this study was to assess whether weekly low-dose bevacizumab-based regimens were well tolerated and would improve efficacy in MBC patients who had failed numerous ther...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12627

    authors: Zhai X,Hong R,Fan Y,Yuan P,Wang J,Sang D,Chen J,Zhao C,Ou K,Ma F,Xu B

    更新日期:2018-05-01 00:00:00

  • Analysis of the associated factors for severe weight loss after minimally invasive McKeown esophagectomy.

    abstract:BACKGROUND:This study investigated the risk factors for severe weight loss (SWL) within one year after minimally invasive McKeown esophagectomy. METHODS:Esophageal cancer patients who underwent McKeown esophagectomy between January and July 2017 were prospectively enrolled. Preoperative body weight (PBW) was chosen as...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12934

    authors: Wang P,Li Y,Sun H,Zhang R,Liu X,Liu S,Wang Z,Zheng Y,Yu Y,Chen X,Li H,Zhang J,Liu Q

    更新日期:2019-02-01 00:00:00